Mebendazole | CAS 31431-39-7 | Benzimidazole Anthelmintic (Research Use Only) | Knowlux

Product Description

Mebendazole, CAS 31431-39-7, is a synthetic benzimidazole anthelmintic supplied by Knowlux for laboratory research use. It is also known as methyl 5-benzoyl-2-benzimidazolecarbamate. The molecular formula is C16H13N3O3 and the molecular weight is 295.29 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Regulatory and form clarification: Mebendazole is approved by the FDA as a prescription medicine (EMVERM) for intestinal worm infections caused by pinworm, whipworm, roundworm, and hookworm in adults and children aged 2 years and older. It is not a permitted dietary-supplement ingredient. Commercial listings describe mebendazole as an antiparasitic or deworming agent; those designations attach to the approved pharmaceutical product or veterinary use and do not apply to, and are not represented by, this research-grade lot.

Product Parameters

Product Details

1. Overview

Mebendazole is a broad-spectrum benzimidazole anthelmintic that has been used clinically since the 1970s for the treatment of intestinal nematode infections. It is poorly absorbed from the gastrointestinal tract, which limits systemic exposure and allows the drug to act locally on intestinal parasites. The FDA-approved EMVERM formulation is indicated for pinworm (enterobiasis), whipworm (trichuriasis), roundworm (ascariasis), and hookworm infections, with reported cure rates of 95%, 68%, 98%, and 96%, respectively. Knowlux supplies mebendazole as a research-grade material for laboratory and analytical use; this supply is not intended for human or veterinary administration and does not constitute a finished drug product.

2. Mechanism of Action (Research Context)

Published research describes mebendazole as a benzimidazole that selectively inhibits microtubule synthesis in parasitic worms. By binding to tubulin and preventing its polymerisation, mebendazole destroys cytoplasmic microtubules in the intestinal cells of helminths, blocking glucose uptake and depleting glycogen reserves. This energy deprivation leads to gradual immobilisation and eventual death of the parasite. The selectivity for parasite tubulin over mammalian tubulin is the basis for its safety margin in approved therapeutic use. These descriptions are derived from published research and are provided for scientific reference only. Knowlux makes no claims regarding the efficacy, safety, or suitability of this product for any human or veterinary application. Promotion of mebendazole for deworming, antiparasitic treatment, or any clinical indication is not supported by Knowlux and is inconsistent with research-use-only supply.

3. Quality Control

4. Applications

• Reference standard for mebendazole analytical method development

• In vitro tubulin binding and microtubule polymerisation studies

• Anthelmintic mechanism research models

• Veterinary parasitology research models

• LC-MS and biochemical assay calibrators

5. Packaging, Storage & Shipping

Powder: amber glass vial or high-barrier foil bag under nitrogen headspace, sealed with tamper-evident closure. Secondary packing: light-protected carton with desiccant. Ambient or cold-chain shipping with temperature logger where required. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, heavy metal statement. Specification summaries and audit support available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Mebendazole is approved as a prescription medicine (EMVERM) in the United States for specific intestinal worm infections; that regulatory status is specific to the approved pharmaceutical product and does not extend to this research-grade supply as sold by Knowlux. Mebendazole carries a GHS classification of H302 (harmful if swallowed); appropriate handling precautions should be observed. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.